BioMarin Delays Hemophilia A Therapy Filing as FDA Calls for More Data

The U.S. Food and Drug Administration has requested additional data for BioMarin Pharmaceutical’s Biologics License Application (BLA) for its hemophilia A therapy, valoctocogene roxaparvovec.